scholarly journals Effects of Dehydroepiandrostenedione, Superimposed on Growth Hormone Substitution, on Quality of Life and Insulin-Like Growth Factor I in Patients with Secondary Adrenal Insufficiency: A Randomized, Placebo-Controlled, Cross-Over Trial

2005 ◽  
Vol 90 (6) ◽  
pp. 3295-3303 ◽  
Author(s):  
Sjoerd W. van Thiel ◽  
Johannes A. Romijn ◽  
Alberto M. Pereira ◽  
Nienke R. Biermasz ◽  
Ferdinand Roelfsema ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Growth Hormone ◽  
Growth Factor ◽  
Adrenal Insufficiency ◽  
Insulin Like Growth Factor ◽  
Secondary Adrenal Insufficiency ◽  
Hormone Substitution ◽  
Factor I ◽  
Growth Factor I

scholarly journals Multicenter, Observational Study of Lanreotide Autogel for the Treatment of Patients with Acromegaly in Routine Clinical Practice in Germany, Austria and Switzerland

2020 ◽  
Author(s):  
Sylvère Störmann ◽  
Jochen Schopohl ◽  
Catharina Bullmann ◽  
Christoph Terkamp ◽  
Mirjam Christ-Crain ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Growth Hormone ◽  
Growth Factor ◽  
Real World ◽  
Insulin Like Growth Factor ◽  
Biochemical Control ◽  
Factor I ◽  
Lanreotide Autogel

Abstract Background Evidence from controlled trials has shown that lanreotide autogel is effective in achieving biochemical and symptom control in patients with acromegaly. However, it is important to better understand the real-world patient population receiving lanreotide autogel treatment. Methods In this non-interventional study the long-term treatment response to lanreotide autogel in adult patients with acromegaly from office-based centers or clinics in Germany, Austria and Switzerland was studied. Assessments included growth hormone and insulin-like growth factor-I levels, symptoms, quality of life, lanreotide plasma levels and tumor somatostatin receptor subtype expression. The primary endpoint was achievement of full biochemical control, defined as growth hormone ≤2.5 µg/L and insulin-like growth factor I normalization at month 12. Results 76 patients were enrolled from 21 sites. 7/51 (13.7%) patients of the efficacy population had full biochemical control at baseline, 15/33 (45.5%) at month 12 and 10/26 (38.5%) at month 24 of treatment. At 12 months of treatment higher rates of biochemical control were observed in the following subgroups: older patients (>53 years [median]), females, treatment-naïve patients, and patients with a time since diagnosis of longer than 1.4 years (median). No clinically relevant differences in acromegaly symptoms or quality of life scores were observed. Median fasting blood glucose and glycated hemoglobin levels remained unchanged throughout the study. No new safety signals were observed. Overall tolerability of treatment with lanreotide autogel was judged by 80.8% of the enrolled patients at month 12 as ‘very good’ or ‘good’. Conclusion Treatment with lanreotide autogel in a real-world setting showed long-term effectiveness and good tolerability in patients with acromegaly.

Insulin-like growth factor-I restores the reduced somatostatinergic tone controlling growth hormone secretion in cirrhotic rats

2001 ◽  
Vol 21 (6) ◽  
pp. 405-409 ◽  
Author(s):  
Inma Castilla-Cortázar ◽  
M. Aurelia Aliaga-Montilla ◽  
Javier Salvador ◽  
María García ◽  
Gloria Delgado ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Growth Factor ◽  
Hormone Secretion ◽  
Growth Hormone Secretion ◽  
Insulin Like Growth Factor ◽  
Factor I ◽  
Growth Factor I

Effects of environmental salinity on somatic growth and growth hormone/insulin-like growth factor-I axis in juvenile tilapia Oreochromis mossambicus

2007 ◽  
Vol 73 (5) ◽  
pp. 1025-1034 ◽  
Author(s):  
Sameh MAGDELDIN ◽  
Katsuhisa UCHIDA ◽  
Tetsuya HIRANO ◽  
E Gordon GRAU ◽  
Ahmed ABDELFATTAH ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Growth Factor ◽  
Somatic Growth ◽  
Oreochromis Mossambicus ◽  
Insulin Like Growth Factor ◽  
Environmental Salinity ◽  
Factor I ◽  
Growth Factor I
Sign in / Sign up

Export Citation Format

Share Document